A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer

被引：0
|
作者：
Boukovinas, I. [1 ]
Androulakis, N. [1 ]
Polyzos, A. [1 ]
Vardakis, N. [1 ]
Amarantidis, K. [1 ]
Bozionelou, V. [1 ]
Kouroussis, C. [1 ]
Giassas, S. [1 ]
Christophyllakis, C. [1 ]
Mavroudis, D. [1 ]
机构：
[1] Hellen Oncol Res Grp, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4536
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase II Study of 5-Fluorouracil/Leucovorin in Combination with Paclitaxel and Oxaliplatin as First-Line Treatment for Patients with Advanced Gastric Cancer
    Lin, Rong-Bo
    Fan, Nan-Feng
    Guo, Zeng-Qing
    Wang, Xiao-Jie
    Liu, Jie
    Chen, Ling
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (06) : 744 - 748
  • [22] First-line treatment of advanced gastric cancer and hepatic dysfunction with oxaliplatin, 5-fluorouracil and cetuximab
    Andrés Jesús Muñoz Martín
    Virginia Martínez Marín
    Juan Luis Arranz Cózar
    Luis Cabezón Gutiérrez
    Ricardo González del Val Subirats
    Pilar García Alfonso
    Clinical and Translational Oncology, 2008, 10 : 182 - 184
  • [23] First-line treatment of advanced gastric cancer and hepatic dysfunction with oxaliplatin, 5-fluorouracil and cetuximab
    Munoz Martin, Andres Jesus
    Martinez Marin, Virginia
    Arranz Cozar, Juan Luis
    Cabezon Gutierrez, Luis
    del Val Subirats, Ricardo Gonzalez
    Garcia Alfonso, Pilar
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (03): : 182 - 184
  • [24] PHASE II STUDY OF FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) WITH GONO-FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) PLUS BEVACIZUMAB (BV)
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Ciprotti, M.
    Donati, S.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 137
  • [25] A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
    Yang Lin
    Song Yan
    Zhou Ai-ping
    Qin Qiong
    Chi Yihebali
    Huang Jing
    Wang Jin-wan
    CHINESE MEDICAL JOURNAL, 2013, 126 (18) : 3470 - 3474
  • [26] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] A phase II study of irinotecan, oxaliplatin, 5-fluorouracil, leucovorin (FOLFOXIRI) as a first-line chemotherapy in metastatic gastric cancer.
    Lee, J.
    Kang, W.
    Lee, S.
    Kwon, J.
    Kim, H.
    Lee, H.
    Lim, H.
    Park, J.
    Park, Y.
    Park, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 197S - 197S
  • [28] Weekly oxaliplatin (OXA), 5-fluorouracil (FU) and leucovorin (LV) as first line treatment for advanced colorectal cancer (CRC) - A phase II study.
    Tsavdaridis, D
    Athanasiadis, A
    Pissanidis, N
    Saleh, M
    Moshidis, A
    Chatzichristou, A
    Makrantonakis, N
    Kamentsidis, P
    Natsiopoulos, I
    Christakis, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 297S - 297S
  • [29] Bevacizumab plus oxaliplatin (LOHP), leukovorin (LV)/5-fluorouracil (5-FU) (FOLFOX4) as first line treatment of patients with metastatic colorectal cancer(MCC)
    Emmanouilides, C.
    Sfakiotaki, G.
    Souglakos, J.
    Mavroudis, D.
    Androulakis, N.
    Kavlaki, A.
    Kotsakis, A.
    Diamandidou, E.
    Touroutoglou, N.
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 71
  • [30] Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial
    Souglakos, J
    Mavroudis, D
    Kakolyris, S
    Kourousis, C
    Vardakis, N
    Androulakis, N
    Agelaki, S
    Kalbakis, K
    Tsetis, D
    Athanasiadis, N
    Samonis, G
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2651 - 2657
12345